This is an extract - CST - ASX release dated 2/10/02
"Cellestis Ltd ("CST") has today signed a contract with Statens Serum Institut ("SS"), a Danish Government owned company. SSI is a world leader in tuberculosis research, and a major European producer of vaccines and other biological products. The contract grants Cellestis the exclusive rights to use SSI's owned and licensed tuberculosis specific proteins in CST's QuantiFERON technology. These rights cover the most significant proteins that are known to be specific to tuberculosis, and include patent coverage in major markets and countries until 2015 and beyond."
CST Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held